多发性硬化症合并症——呼吁跨学科合作以提高MS患者的生活质量。

IF 2.1 Q3 CLINICAL NEUROLOGY
Degenerative neurological and neuromuscular disease Pub Date : 2019-06-13 eCollection Date: 2019-01-01 DOI:10.2147/DNND.S204555
Hans-Klaus Goischke
{"title":"多发性硬化症合并症——呼吁跨学科合作以提高MS患者的生活质量。","authors":"Hans-Klaus Goischke","doi":"10.2147/DNND.S204555","DOIUrl":null,"url":null,"abstract":"<p><p>The negative influence of comorbidities on the quality of life of people with multiple sclerosis is evident and the problem is increasingly acknowledged by numerous international studies in long-term care. One therapeutic option would be an add-on therapy with vitamin D (VD), with the aim of achieving a therapeutically effective dose. The individually required VD dose must be tested, since the response to a certain dose is subject to variations between individuals. A possible toxicity with increased 1.25(OH)D3 (active VD metabolite) is largely prevented by increased activity of 24-hydroxylase (<i>CYP24A1</i>). Monitoring of serum VD levels as well as serum calcium and phosphate levels (optional Ca excretion in 24-hour urine, Ca creatinine ratio in urine) provides safety and is necessary because possible mutations on the (catabolic) <i>CYP24A1</i> gene can lead to a partial or total loss of 24-hydroxylase activity and provoke hypercalcemia/hyperphosphatemia. The main therapeutic objective is to maintain functional and social independence by using drugs with a high safety profile. The prevention and optimal management of comorbidities can influence the quality of life of patients with MS (PwMS) when included in patient care. Adequate measures can reduce the burden of MS only if the risk of comorbidity is reduced through targeted monitoring, early detection and diagnosis. Such a strategy will contribute to influencing the premature mortality of patients with MS. If VD is recognized as a \"multipurpose steroid hormone\", it could also be used to maintain cognitive function and prevent premature possible dementia, especially as there is evidence that VD deficiency correlates with brain atrophy (hippocampus). At present, MS therapy is still a balancing act between therapeutically efficient action and the management of unexpected side effects, with VD add-on therapy being almost unproblematic and most likely to be accepted by PwMS.</p>","PeriodicalId":93972,"journal":{"name":"Degenerative neurological and neuromuscular disease","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2019-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/8a/dnnd-9-39.PMC6584285.pdf","citationCount":"0","resultStr":"{\"title\":\"Comorbidities in multiple sclerosis-a plea for interdisciplinary collaboration to improve the quality of life of MS patients.\",\"authors\":\"Hans-Klaus Goischke\",\"doi\":\"10.2147/DNND.S204555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The negative influence of comorbidities on the quality of life of people with multiple sclerosis is evident and the problem is increasingly acknowledged by numerous international studies in long-term care. One therapeutic option would be an add-on therapy with vitamin D (VD), with the aim of achieving a therapeutically effective dose. The individually required VD dose must be tested, since the response to a certain dose is subject to variations between individuals. A possible toxicity with increased 1.25(OH)D3 (active VD metabolite) is largely prevented by increased activity of 24-hydroxylase (<i>CYP24A1</i>). Monitoring of serum VD levels as well as serum calcium and phosphate levels (optional Ca excretion in 24-hour urine, Ca creatinine ratio in urine) provides safety and is necessary because possible mutations on the (catabolic) <i>CYP24A1</i> gene can lead to a partial or total loss of 24-hydroxylase activity and provoke hypercalcemia/hyperphosphatemia. The main therapeutic objective is to maintain functional and social independence by using drugs with a high safety profile. The prevention and optimal management of comorbidities can influence the quality of life of patients with MS (PwMS) when included in patient care. Adequate measures can reduce the burden of MS only if the risk of comorbidity is reduced through targeted monitoring, early detection and diagnosis. Such a strategy will contribute to influencing the premature mortality of patients with MS. If VD is recognized as a \\\"multipurpose steroid hormone\\\", it could also be used to maintain cognitive function and prevent premature possible dementia, especially as there is evidence that VD deficiency correlates with brain atrophy (hippocampus). At present, MS therapy is still a balancing act between therapeutically efficient action and the management of unexpected side effects, with VD add-on therapy being almost unproblematic and most likely to be accepted by PwMS.</p>\",\"PeriodicalId\":93972,\"journal\":{\"name\":\"Degenerative neurological and neuromuscular disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2019-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/8a/dnnd-9-39.PMC6584285.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Degenerative neurological and neuromuscular disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/DNND.S204555\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Degenerative neurological and neuromuscular disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/DNND.S204555","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

合并症对多发性硬化症患者生活质量的负面影响是显而易见的,长期护理领域的许多国际研究越来越认识到这个问题。一种治疗选择是使用维生素D(VD)进行附加治疗,目的是达到治疗有效剂量。必须测试个人所需的VD剂量,因为对特定剂量的反应会因个人而异。1.25(OH)D3(活性VD代谢产物)增加的可能毒性在很大程度上通过增加24-羟化酶(CYP24A1)的活性来预防。监测血清VD水平以及血清钙和磷酸盐水平(24小时尿液中可选的钙排泄量、尿液中的钙-肌酸酐比率)提供了安全性,并且是必要的,因为(分解代谢)CYP24A1基因上可能的突变会导致24-羟化酶活性的部分或全部丧失,并引发高钙血症/高磷血症。主要治疗目标是通过使用具有高安全性的药物来保持功能和社会独立性。当纳入患者护理时,合并症的预防和最佳管理会影响多发性硬化症患者的生活质量。只有通过有针对性的监测、早期发现和诊断来降低合并症的风险,适当的措施才能减轻多发性硬化症的负担。这种策略将有助于影响多发性硬化症患者的过早死亡。如果VD被认为是一种“多用途类固醇激素”,它也可以用于维持认知功能和预防可能的过早痴呆,特别是有证据表明VD缺乏与脑萎缩(海马体)相关。目前,多发性硬化症治疗仍然是治疗有效作用和意外副作用管理之间的平衡行为,VD附加治疗几乎没有问题,最有可能被PwMS接受。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comorbidities in multiple sclerosis-a plea for interdisciplinary collaboration to improve the quality of life of MS patients.

The negative influence of comorbidities on the quality of life of people with multiple sclerosis is evident and the problem is increasingly acknowledged by numerous international studies in long-term care. One therapeutic option would be an add-on therapy with vitamin D (VD), with the aim of achieving a therapeutically effective dose. The individually required VD dose must be tested, since the response to a certain dose is subject to variations between individuals. A possible toxicity with increased 1.25(OH)D3 (active VD metabolite) is largely prevented by increased activity of 24-hydroxylase (CYP24A1). Monitoring of serum VD levels as well as serum calcium and phosphate levels (optional Ca excretion in 24-hour urine, Ca creatinine ratio in urine) provides safety and is necessary because possible mutations on the (catabolic) CYP24A1 gene can lead to a partial or total loss of 24-hydroxylase activity and provoke hypercalcemia/hyperphosphatemia. The main therapeutic objective is to maintain functional and social independence by using drugs with a high safety profile. The prevention and optimal management of comorbidities can influence the quality of life of patients with MS (PwMS) when included in patient care. Adequate measures can reduce the burden of MS only if the risk of comorbidity is reduced through targeted monitoring, early detection and diagnosis. Such a strategy will contribute to influencing the premature mortality of patients with MS. If VD is recognized as a "multipurpose steroid hormone", it could also be used to maintain cognitive function and prevent premature possible dementia, especially as there is evidence that VD deficiency correlates with brain atrophy (hippocampus). At present, MS therapy is still a balancing act between therapeutically efficient action and the management of unexpected side effects, with VD add-on therapy being almost unproblematic and most likely to be accepted by PwMS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信